CIBC Private Wealth Group LLC lessened its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 3.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 44,911 shares of the company’s stock after selling 1,720 shares during the quarter. CIBC Private Wealth Group LLC owned approximately 0.11% of Omnicell worth $3,631,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in OMCL. Parallel Advisors LLC bought a new stake in shares of Omnicell in the first quarter valued at approximately $28,000. Bronfman E.L. Rothschild L.P. increased its holdings in Omnicell by 451.8% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 618 shares of the company’s stock valued at $38,000 after purchasing an additional 506 shares during the period. Nisa Investment Advisors LLC increased its holdings in Omnicell by 125.0% in the first quarter. Nisa Investment Advisors LLC now owns 540 shares of the company’s stock valued at $44,000 after purchasing an additional 300 shares during the period. IFP Advisors Inc increased its holdings in Omnicell by 109.3% in the fourth quarter. IFP Advisors Inc now owns 741 shares of the company’s stock valued at $45,000 after purchasing an additional 387 shares during the period. Finally, Manchester Capital Management LLC acquired a new stake in Omnicell in the first quarter valued at $49,000. 97.30% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:OMCL traded down $2.60 on Wednesday, hitting $83.79. The stock had a trading volume of 310,912 shares, compared to its average volume of 322,917. The firm’s fifty day simple moving average is $82.48. The company has a current ratio of 1.96, a quick ratio of 1.47 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 1 year low of $51.55 and a 1 year high of $92.59. The firm has a market cap of $3.45 billion, a PE ratio of 54.76, a P/E/G ratio of 2.85 and a beta of 1.15.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, April 25th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.23 by $0.38. Omnicell had a net margin of 4.74% and a return on equity of 11.10%. The company had revenue of $202.50 million during the quarter, compared to analyst estimates of $199.72 million. During the same quarter last year, the business posted $0.29 EPS. Omnicell’s quarterly revenue was up 10.9% compared to the same quarter last year. Research analysts expect that Omnicell, Inc. will post 2.06 EPS for the current fiscal year.
A number of analysts recently weighed in on the company. BidaskClub upgraded Omnicell from a “hold” rating to a “buy” rating in a report on Thursday, June 20th. Zacks Investment Research downgraded Omnicell from a “hold” rating to a “sell” rating in a report on Monday, March 4th. ValuEngine upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Finally, Dougherty & Co increased their price target on Omnicell from $78.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, March 7th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $79.89.
In other news, insider Joseph Brian Spears sold 6,450 shares of Omnicell stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $79.62, for a total transaction of $513,549.00. Following the completion of the sale, the insider now directly owns 19,112 shares of the company’s stock, valued at approximately $1,521,697.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Peter J. Kuipers sold 13,000 shares of Omnicell stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $81.62, for a total transaction of $1,061,060.00. Following the sale, the insider now directly owns 55,829 shares of the company’s stock, valued at $4,556,762.98. The disclosure for this sale can be found here. Insiders sold a total of 136,099 shares of company stock valued at $9,893,007 over the last quarter. 2.77% of the stock is owned by company insiders.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Recommended Story: NASDAQ
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.